Table 4

Treatment-emergent adverse events

Adverse eventsMavrilimumab*
(N=42)
Placebo
(N=28)
Patients with ≥1 adverse event33 (78.6%)25 (89.3%)
Serious adverse event2 (4.8%)3 (10.7%)
Serious adverse event related to study drug00
Adverse event resulting in death00
Adverse event leading to study drug discontinuation1 (2.4%)1 (3.6%)
Adverse events by maximum severity†
 Mild18 (42.9%)13 (46.4%)
 Moderate14 (33.3%)11 (39.3%)
 Severe1 (2.4%)1 (3.6%)
Most common adverse events‡
 Headache6 (14.3%)7 (25.0%)
 Nasopharyngitis5 (11.9%)3 (10.7%)
 Neck pain4 (9.5%)2 (7.1%)
 Arthralgia2 (4.8%)4 (14.3%)
 Hypertension1 (2.4%)4 (14.3%)
 Back pain3 (7.1%)3 (10.7%)
 Muscle spasms3 (7.1%)3 (10.7%)
 Upper respiratory tract infection3 (7.1%)2 (7.1%)
 Constipation3 (7.1%)0
 Diarrhoea03 (10.7%)
 Fall2 (4.8%)5 (17.9%)
  • Data are n (%).

  • *150 mg subcutaneously every 2 weeks.

  • †Each patient is represented only with maximum severity.

  • ‡Reported in >2 patients in either treatment group.